

Mail Stop 6010

April 10, 2009

John F. Crowley  
President and Chief Executive Officer  
Amicus Therapeutics, Inc.  
6 Cedar Brook Drive  
Cranbury, NJ 08512

**Re: Amicus Therapeutics, Inc.  
Form 10-K  
Filed February 8, 2008, response filed March 30, 2009  
File No. 001-33497**

Dear Mr. Crowley:

We have reviewed your filing and have the following comments. Where indicated, we think you should revise your document in response to these comments. If you disagree, we will consider your explanation as to why our comment is inapplicable or a revision is unnecessary. Please be as detailed as necessary in your explanation. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. After reviewing this information, we may raise additional comments.

Please understand that the purpose of our review process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comments or any other aspect of our review. Feel free to call us at the telephone numbers listed at the end of this letter.

#### General

1. We note your response to comment 1. Much of the information you believe is confidential and is likely to cause competitive harm if disclosed is actually disclosed in your Form 10-K. For example,
  - Your 10-K discloses that you have completed a Phase II clinical trial related to Fabry disease;
  - You are currently conducting a Phase II clinical trial of Plicera for Gaucher disease;

- You are currently conducting a Phase II clinical trial for AT2220 for the treatment of Pompe disease.

Please review the goals that you believe are confidential and are likely to cause competitive harm if disclosed to determine which information has already been disclosed. To the extent that the information has been disclosed, it is not appropriate for you to request confidential treatment pursuant to Rule 83.

\* \* \*

As appropriate, please amend your filing and respond to these comments within 10 business days or tell us when you will provide us with a response. You may wish to provide us with marked copies of the amendment to expedite our review. Please furnish a cover letter with your amendment that keys your responses to our comments and provides any requested information. Detailed cover letters greatly facilitate our review. Please understand that we may have additional comments after reviewing your amendment and responses to our comments.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes all information required under the Securities Exchange Act of 1934 and that they have provided all information investors require for an informed investment decision. Since the company and its management are in possession of all facts relating to a company's disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

In connection with responding to our comments, please provide, in writing, a statement from the company acknowledging that:

- the company is responsible for the adequacy and accuracy of the disclosure in the filing;
- staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
- the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

In addition, please be advised that the Division of Enforcement has access to all information you provide to the staff of the Division of Corporation Finance in our review of your filing or in response to our comments on your filing.

John F. Crowley  
Amicus Therapeutics, Inc.  
April 10, 2009  
Page 3 of 3

Please contact Mike Rosenthal at 202-551-3674 or me at 202-551-3715 with any other questions.

Sincerely,

Jeffrey P. Riedler  
Assistant Director

cc: Julio E. Vega  
Noreen A. Martin  
Bingham McCutchen LLP  
Fax: 617.951.8736